샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798196

세계의 애완동물 암 치료 시장

Pet Cancer Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 384 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 애완동물 암 치료 시장은 2030년까지 6억 2,460만 달러에 달할 전망

2024년에 4억 3,090만 달러로 추정되는 세계의 애완동물 암 치료 시장은 분석 기간인 2024-2030년에 CAGR 6.4%로 성장하며, 2030년에는 6억 2,460만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 화학요법은 CAGR 6.7%를 기록하며, 분석 기간 종료시에는 2억 1,840만 달러에 달할 것으로 예측됩니다. 방사선 요법 분야의 성장률은 분석 기간 중 CAGR 4.6%로 추정됩니다.

미국 시장은 1억 1,740만 달러로 추정, 중국은 CAGR 10.1%로 성장 예측

미국의 애완동물 암 치료 시장은 2024년에 1억 1,740만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 2,860만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 10.1%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.2%와 6.2%로 예측됩니다. 유럽에서는 독일이 CAGR 4.2%로 성장할 것으로 예측됩니다.

세계의 애완동물 암 치료 시장 - 주요 동향과 촉진요인 정리

애완동물 암 치료가 수의학에서 우선순위로 떠오르는 이유는 무엇인가?

애완동물 암 치료는 반려동물의 수명 연장, 수의학적 지출 증가, 인간 종양학과 유사한 고급 치료를 원하는 보호자 증가 추세로 인해 수의학 의료 분야에서 가장 역동적인 분야 중 하나로 발전하고 있습니다. 암은 노령견과 노령묘의 주요 사망 원인으로 림프종, 비만세포종, 골육종, 흑색종, 혈관육종 등이 유행하고 있습니다. 반려동물을 키우는 것이 정서적, 경제적으로 큰 비중을 차지하게 되면서 암 진단을 받은 반려동물의 조기 발견, 효과적인 치료, 삶의 질 유지에 대한 요구가 높아지고 있습니다.

디지털 엑스레이 검사, CT 스캔, 세침흡인세포검사, 면역조직화학검사 등을 전문 클리닉에서 이용할 수 있게 되면서 종양을 조기에 발견하고 분류할 수 있게 되어 진단법이 크게 향상되었습니다. 그 결과, 치료 참여가 증가했습니다. 현재 수의 종양 전문의는 화학요법, 표적치료제, 면역요법, 수술적 종양학, 방사선 치료 등 보다 다양한 치료법을 이용할 수 있습니다. 이러한 치료법은 이전에는 대학 부속 센터에 국한되어 있었으나, 현재는 상업적인 동물병원 체인이나 도심의 진료소까지 확대되고 있습니다.

반려동물을 위한 보험, 웰니스 플랜, 반려동물에 특화된 종양학 진단의 개발도 병행되고 있으며, 수요를 촉진하고 있습니다. 반려동물 보호자들은 치료 목적과 완화치료의 두 가지 옵션을 모두 제공하는 치료를 점점 더 많이 요구하고 있습니다. 종을 넘나드는 임상시험과 바이오마커 발굴을 기반으로 한 인간과 수의학 종양학 연구의 융합은 기술 혁신을 촉진하고 수의학 시장에 맞는 번역 치료를 가능하게 하고 있습니다.

어떤 치료 혁신이 수의학 종양학을 재구성하고 있는가?

애완동물 암 치료 시장에서 가장 주목할 만한 변화는 일반적인 화학요법에서 표적치료와 면역치료 접근법으로의 전환입니다. 모노클로널 항체(예: 아라타나 테라퓨틱스의 브론트리스, 택트리스 등)와 저분자 억제제는 특정 종양 항원이나 증식 경로를 표적으로 삼아 생존율을 높이고 전신 독성을 최소화하기 위해 사용되고 있습니다. 토세라닙 인산염(파라디아)과 같은 티로신 키나아제 억제제는 현재 반려견 비만세포종에 일상적으로 사용되고 있습니다.

암 백신과 체크포인트 억제제를 포함한 면역요법은 보조 또는 단독 치료로 부상하고 있습니다. 개 흑색종 백신(Oncept)은 경구용 흑색종 반려견의 생존기간을 연장하는 데 유망하며, 다른 자가백신 플랫폼도 혈관육종과 림프종을 대상으로 개발 중입니다. 유전자 치료도 초기 단계부터 검토되고 있으며, 벡터 기반 종양 억제 유전자 도입 및 면역 조절에 대한 시험이 진행되고 있습니다.

진단 측면에서는 종양의 진행과 재발을 모니터링하기 위한 비침습적 툴로 액체생검과 순환종양세포(CTC) 검출이 검토되고 있습니다. AI 기반 증상 추적기, 원격 수의학 상담 등 디지털 헬스 툴은 암 초기 증상 파악과 치료 후 모니터링에 도움을 주고 있습니다. 이러한 기술 혁신은 임상 상황을 변화시키고 있으며, 반려동물의 맞춤형 데이터베이스 암 관리를 가능하게 하고 있습니다.

반려동물용 항암제 보급을 주도하는 분야와 시장은?

개는 여전히 수의종양학에서 가장 큰 환자 집단이며, 진단율과 치료율은 고양이보다 훨씬 높습니다. 골든 리트리버, 복서, 버니즈 마운틴 도그 등의 견종은 특정 암에 대한 유전적 소인을 가지고 있으며, 도시 고소득층 반려동물 소유자층에 수요가 집중되어 있습니다. 고양이는 진단 빈도가 낮지만, 고양이 특유의 암 치료제, 특히 림프종과 편평상피암에 대한 관심이 높아지고 있습니다.

시장 침투율이 가장 높은 곳은 북미, 특히 미국으로 고급 동물병원, 종양내과 전문의, 보험 진료가 널리 보급되어 있습니다. 유럽은 그 뒤를 이어 영국, 독일, 네덜란드 등의 국가에서는 반려동물 의약품에 대한 인식과 규제적 지원으로 높은 치료 도입률이 보고되고 있습니다. 아시아태평양은 급성장하는 지역으로, 특히 일본, 한국, 중국, 인도 등 도시 지역에서는 반려동물의 인간화 추세가 전문 의료에 대한 새로운 투자를 촉발하고 있습니다.

동물병원, 동물병원, 진단연구소가 주요 공급망을 형성하고 있습니다. 화학요법, 방사선 치료, 외과적 종양학을 제공하는 전문 의료센터가 대도시권에서 성장하고 있습니다. 또한 반려동물 보험사들은 암 치료, 진단, 사후관리까지 포함하는 보험을 확대하는 추세입니다.

세계 애완동물 암 치료 시장의 성장을 주도하는 요인은 무엇인가?

세계 애완동물 암 치료 시장의 성장을 주도하는 것은 반려동물의 수명 연장, 반려동물 보호자들의 첨단 의료에 대한 투자 의향 증가, 진단 및 치료 기술에 대한 접근성 확대, 수의학에서의 표적 치료 및 면역 종양학의 부상입니다. 반려동물의 인간화 추세가 심화됨에 따라 암 치료는 완화치료 지원에서 적극적이고 정밀한 개입으로 전환되고 있습니다.

반려동물 보험의 보급 확대, 수의사 수의사 수 증가, 발견율 향상으로 인한 암 유병률 증가가 치료법의 보급을 가속화하고 있습니다. 동물용의약품에 대한 규제 지원과 임상 승인 경로의 간소화도 새로운 치료제의 신속한 상용화를 가능하게 하고 있습니다. 인간 종양학의 진보를 활용하여 동물용 프로토콜에 반영하는 중개연구 동향은 혁신을 더욱 촉진하고 있습니다.

반려동물 사육률 증가, 반려동물의 고령화, 약물전달, 종양유전학, 맞춤의료의 기술적 도약에 힘입어 종양학은 현재 수의학 전문분야의 핵심을 이루고 있으며, 반려동물 암치료 시장은 앞으로도 계속 상승세를 이어갈 것으로 예측됩니다.

부문

요법(화학요법, 방사선 요법, 면역치료, 표적치료, 기타 요법); 동물(개, 고양이, 기타 동물); 용도(림프종 용도, 비만세포 암용도, 흑색종 용도, 유선·편평상피암 용도, 기타 용도)

조사 대상 기업의 예

  • AB Science
  • Akston Biosciences
  • Anivive Lifesciences
  • Boehringer Ingelheim
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • ImpriMed
  • Karyopharm Therapeutics
  • LiteCure LLC
  • Mars Petcare
  • Merck Animal Health(MSD)
  • Nippon Zenyaku Kogyo(Zenoaq)
  • Norbrook Laboratories
  • Oasmia Pharmaceuticals
  • PetCure Oncology
  • Pfizer(Zoetis)
  • QBiotics Group Ltd.
  • Regeneus Ltd.
  • SpyBiotech
  • VetDC Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.09.04

Global Pet Cancer Therapeutics Market to Reach US$624.6 Million by 2030

The global market for Pet Cancer Therapeutics estimated at US$430.9 Million in the year 2024, is expected to reach US$624.6 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$218.4 Million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$117.4 Million While China is Forecast to Grow at 10.1% CAGR

The Pet Cancer Therapeutics market in the U.S. is estimated at US$117.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$128.6 Million by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Pet Cancer Therapeutics Market - Key Trends & Drivers Summarized

Why Is Cancer Care in Pets Emerging as a Priority in Veterinary Medicine?

Pet cancer therapeutics is evolving into one of the most dynamic segments in veterinary healthcare, driven by rising pet lifespans, increased veterinary expenditure, and a growing tendency among pet owners to pursue advanced care similar to human oncology. Cancer is the leading cause of death in older dogs and cats, with prevalent forms including lymphoma, mast cell tumors, osteosarcoma, melanoma, and hemangiosarcoma. As pet ownership becomes more emotionally and economically involved, there is a rising demand for early detection, effective treatment, and quality-of-life maintenance in companion animals diagnosed with cancer.

Diagnostics have improved markedly, with the availability of digital radiography, CT scans, fine-needle aspiration cytology, and immunohistochemistry in specialty clinics enabling early-stage identification and classification of tumors. This, in turn, has increased therapeutic uptake. Veterinary oncologists now have access to a wider arsenal of interventions, including chemotherapy, targeted drugs, immunotherapy, surgical oncology, and radiation therapy. These interventions were previously limited to university-affiliated centers but are now expanding into commercial veterinary chains and urban clinics.

Parallel developments in insurance coverage for pets, wellness plans, and pet-focused oncology diagnostics are fueling demand. Pet owners are increasingly seeking treatments that offer both curative intent and palliative care options. The convergence of human and veterinary oncology research, supported by cross-species trials and biomarker identification, is driving innovation and enabling translational therapies tailored to the veterinary market.

What Therapeutic Innovations Are Reshaping Veterinary Oncology?

The most notable shift in the pet cancer therapeutics market is the move from generic chemotherapeutic regimens to targeted and immunotherapeutic approaches. Monoclonal antibodies (e.g., Blontress and Tactress by Aratana Therapeutics) and small-molecule inhibitors are being used to target specific tumor antigens or growth pathways, improving survival and minimizing systemic toxicity. Tyrosine kinase inhibitors such as toceranib phosphate (Palladia) are now routinely used for mast cell tumors in dogs.

Immunotherapies, including cancer vaccines and checkpoint inhibitors, are emerging as adjunctive or standalone treatments. Canine melanoma vaccine (Oncept) has shown promise in extending survival in dogs with oral melanoma, and other autologous vaccine platforms are under development for hemangiosarcoma and lymphoma. Gene therapy is also under early investigation, with trials exploring vector-based tumor suppressor gene delivery and immune modulation.

On the diagnostics side, liquid biopsies and circulating tumor cell (CTC) detection are being explored as non-invasive tools to monitor tumor progression or recurrence. Digital health tools, such as AI-based symptom trackers and tele-veterinary consultations, are helping in early cancer symptom identification and post-treatment monitoring. These innovations are transforming the clinical landscape and enabling more customized, data-driven cancer management in pets.

Which Segments and Markets Are Leading in Pet Oncology Therapeutics Uptake?

Dogs remain the largest patient population for veterinary oncology, with significantly higher diagnosis and treatment rates than cats. Breeds such as Golden Retrievers, Boxers, and Bernese Mountain Dogs show genetic predisposition to certain cancers, leading to demand concentration in urban, high-income pet-owner clusters. Cats, though less frequently diagnosed, are seeing growing attention in feline-specific cancer therapeutics, especially for lymphoma and squamous cell carcinoma.

The highest market penetration exists in North America, particularly the United States, where advanced veterinary hospitals, oncology specialists, and insurance-backed services are widely available. Europe is following closely, with countries like the UK, Germany, and the Netherlands reporting high treatment adoption due to awareness and regulatory support for companion animal drugs. Asia-Pacific is a rapidly growing region, especially in Japan, South Korea, and urban centers in China and India, where pet humanization trends are triggering new investments in specialized care.

Veterinary clinics, pet hospitals, and diagnostic laboratories form the main supply chain. Specialty care centers that offer chemotherapy, radiation, and surgical oncology are growing in metropolitan areas. Pharma companies are increasingly targeting the veterinary oncology space with tailored R&D, while pet insurance providers are broadening coverage policies to include cancer therapies, diagnostics, and follow-up care.

What Is Driving Growth in the Global Pet Cancer Therapeutics Market?

The growth in the global pet cancer therapeutics market is driven by rising pet longevity, increasing willingness among owners to invest in advanced care, growing access to diagnostic and therapeutic technologies, and the emergence of targeted therapies and immuno-oncology in the veterinary sector. As pet humanization trends deepen, cancer treatment is transitioning from palliative support to proactive, precision-based interventions.

Expanding availability of pet insurance, increasing number of veterinary specialists, and rising prevalence of cancer due to better detection are accelerating therapeutic uptake. Regulatory support for veterinary drugs and streamlined clinical approval pathways are also enabling faster commercialization of novel therapies. The trend of translational research-leveraging human oncology advances to inform veterinary protocols-is further supporting innovation.

With oncology now a core pillar of veterinary specialization, the pet cancer therapeutics market is expected to continue its upward trajectory, supported by rising pet adoption rates, aging pet populations, and technological breakthroughs in drug delivery, tumor genetics, and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Pet Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies, Other Therapies); Animal (Dog, Cat, Other Animals); Application (Lymphoma Application, Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AB Science
  • Akston Biosciences
  • Anivive Lifesciences
  • Boehringer Ingelheim
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • ImpriMed
  • Karyopharm Therapeutics
  • LiteCure LLC
  • Mars Petcare
  • Merck Animal Health (MSD)
  • Nippon Zenyaku Kogyo (Zenoaq)
  • Norbrook Laboratories
  • Oasmia Pharmaceuticals
  • PetCure Oncology
  • Pfizer (Zoetis)
  • QBiotics Group Ltd.
  • Regeneus Ltd.
  • SpyBiotech
  • VetDC Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pet Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pet Humanization Trends Throw the Spotlight on Advanced Cancer Treatment for Companion Animals
    • Expansion of Veterinary Oncology Services Drives Demand for Novel Cancer Therapeutics in Pets
    • Increased Life Expectancy of Pets Spurs Growth in Age-Related Cancer Diagnoses and Treatments
    • Advancements in Companion Animal Genomics Strengthen Business Case for Targeted Therapeutics
    • Growing Use of Immunotherapies and Monoclonal Antibodies Expands Pet Cancer Treatment Modalities
    • Veterinary Drug Approvals for Canine and Feline Oncology Indications Accelerate Market Maturity
    • Increased Diagnostic Imaging Capabilities in Veterinary Clinics Enhances Cancer Detection Rates
    • Emergence of AI and Digital Pathology Platforms Improves Tumor Identification and Prognosis
    • Growth of Pet Insurance Coverage Supports Affordability and Uptake of Expensive Oncology Therapies
    • Expansion of Veterinary Clinical Trials Network Spurs Innovation in Pet Cancer Drug Development
    • Development of Oral Chemotherapy Formulations Enhances Compliance in At-Home Treatment
    • Increased Focus on Palliative Care and Quality of Life Drives Demand for Adjunctive Oncology Solutions
    • Collaboration Between Human and Veterinary Oncology Research Communities Enables Technology Transfer
    • Rising Demand for Minimally Invasive Treatment Modalities Fuels Adoption of Precision Radiation Systems
    • Pet Owner Awareness Campaigns and Advocacy Groups Drive Early Detection and Therapy Adoption
    • Integration of Companion Diagnostics in Veterinary Oncology Supports Personalized Treatment Plans
    • Expansion of Specialty Veterinary Clinics and Oncology Hospitals Supports Geographic Market Penetration
    • Veterinary Pharmaceutical Investments in Oncology Pipelines Accelerate Product Launches
    • Regulatory Fast-Track Programs for Animal Health Products Support Timely Market Access
    • Evolving Ethical Considerations and Owner Expectations Promote Holistic Pet Cancer Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pet Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pet Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Targeted Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Targeted Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Mast Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Mast Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Mast Cell Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Mammary & Squamous Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Mammary & Squamous Cell Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Mammary & Squamous Cell Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Lymphoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Dog by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Cat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other Animals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • JAPAN
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • CHINA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • EUROPE
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Pet Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • FRANCE
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • GERMANY
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • INDIA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Pet Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Pet Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030
  • AFRICA
    • Pet Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Pet Cancer Therapeutics by Therapy - Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Pet Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies and Other Therapies for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Pet Cancer Therapeutics by Application - Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Pet Cancer Therapeutics by Application - Percentage Breakdown of Value Sales for Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications and Lymphoma Application for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Pet Cancer Therapeutics by Animal - Dog, Cat and Other Animals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Pet Cancer Therapeutics by Animal - Percentage Breakdown of Value Sales for Dog, Cat and Other Animals for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제